Tianjin TEDA Biomedical Engineering Past Earnings Performance
Past criteria checks 0/6
Tianjin TEDA Biomedical Engineering has been growing earnings at an average annual rate of 41.6%, while the Chemicals industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
41.6%
Earnings growth rate
41.3%
EPS growth rate
| Chemicals Industry Growth | 10.2% |
| Revenue growth rate | 4.2% |
| Return on equity | -4.1% |
| Net Margin | -1.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 73% Price Jump
Oct 17
There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 38% Price Jump
Aug 16Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some Risk
May 07Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?
Sep 12Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% Hiding
Apr 17Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?
Apr 07Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Nov 01Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of Debt
Apr 21Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?
Oct 26Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?
Apr 06Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Dec 22
Revenue & Expenses Breakdown
How Tianjin TEDA Biomedical Engineering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 424 | -7 | 36 | 1 |
| 31 Mar 24 | 417 | -11 | 37 | 1 |
| 31 Dec 23 | 398 | -15 | 39 | 1 |
| 30 Sep 23 | 450 | -24 | 39 | 1 |
| 30 Jun 23 | 384 | -23 | 37 | 1 |
| 31 Mar 23 | 447 | -28 | 41 | 1 |
| 31 Dec 22 | 404 | -25 | 38 | 1 |
| 30 Sep 22 | 424 | -66 | 57 | 3 |
| 30 Jun 22 | 440 | -56 | 53 | 3 |
| 31 Mar 22 | 441 | -48 | 56 | 3 |
| 31 Dec 21 | 476 | -42 | 60 | 3 |
| 30 Sep 21 | 475 | -30 | 60 | 6 |
| 30 Jun 21 | 446 | -42 | 65 | 6 |
| 31 Mar 21 | 425 | -43 | 66 | 6 |
| 31 Dec 20 | 369 | -48 | 60 | 6 |
| 30 Sep 20 | 326 | -86 | 58 | 8 |
| 30 Jun 20 | 323 | -83 | 57 | 8 |
| 31 Mar 20 | 314 | -87 | 57 | 8 |
| 31 Dec 19 | 359 | -85 | 64 | 8 |
| 30 Sep 19 | 367 | -133 | 47 | 12 |
| 30 Jun 19 | 376 | -176 | 53 | 12 |
| 31 Mar 19 | 382 | -174 | 55 | 12 |
| 31 Dec 18 | 352 | -178 | 54 | 12 |
| 30 Sep 18 | 396 | -60 | 60 | 9 |
| 30 Jun 18 | 395 | -16 | 57 | 9 |
| 31 Mar 18 | 391 | -18 | 55 | 9 |
| 31 Dec 17 | 376 | -14 | 51 | 9 |
| 30 Sep 17 | 336 | -19 | 51 | 11 |
| 30 Jun 17 | 337 | -9 | 49 | 11 |
| 31 Mar 17 | 368 | 1 | 50 | 11 |
| 31 Dec 16 | 389 | 6 | 51 | 11 |
| 30 Sep 16 | 382 | 17 | 38 | 15 |
| 30 Jun 16 | 470 | 27 | 41 | 15 |
| 31 Mar 16 | 481 | 24 | 44 | 15 |
| 31 Dec 15 | 502 | 27 | 45 | 15 |
| 30 Sep 15 | 467 | 29 | 24 | 7 |
| 30 Jun 15 | 435 | 20 | 30 | 7 |
| 31 Mar 15 | 442 | 22 | 33 | 7 |
| 31 Dec 14 | 470 | 21 | 37 | 7 |
| 30 Sep 14 | 543 | 20 | 63 | 21 |
| 30 Jun 14 | 541 | 19 | 64 | 21 |
| 31 Mar 14 | 548 | 15 | 69 | 21 |
| 31 Dec 13 | 583 | 21 | 75 | 21 |
Quality Earnings: 8189 is currently unprofitable.
Growing Profit Margin: 8189 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8189 is unprofitable, but has reduced losses over the past 5 years at a rate of 41.6% per year.
Accelerating Growth: Unable to compare 8189's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8189 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-29.6%).
Return on Equity
High ROE: 8189 has a negative Return on Equity (-4.06%), as it is currently unprofitable.